Circulating mesenchymal stem cells in patients with hypertrophic cardiomyopathy

被引：10
|
作者：
Marketou, Maria E. [1 ]
Parthenakis, Fragiskos I. [1 ]
Kalyva, Athanasia [2 ]
Pontikoglou, Charalampos [3 ]
Maragkoudakis, Spyros [1 ]
Kontaraki, Joanna E. [2 ]
Zacharis, Evangelos A. [1 ]
Patrianakos, Alexandros [1 ]
Chlouverakis, Gregory [4 ]
Papadaki, Helen A. [3 ]
Vardas, Panos E. [1 ]
机构：
[1] Heraklion Univ Hosp, Dept Cardiol, Iraklion, Greece
[2] Univ Crete, Sch Med, Mol Cardiol Lab, Iraklion, Greece
[3] Heraklion Univ Hosp, Dept Hematol, Iraklion, Greece
[4] Univ Crete, Sch Med, Div Biostat, Iraklion, Greece
来源：
CARDIOVASCULAR PATHOLOGY | 2015年 / 24卷 / 03期
关键词：
Hypertrophic cardiomyopathy; Mesenchymal stem cells; Flow cytometry; PROGENITOR CELLS; BONE-MARROW; DISEASE; TRANSPLANTATION; EXPRESSION; MODEL; CORD;
D O I：
10.1016/j.carpath.2015.02.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background: This study examines the mobilization of mesenchymal stemcells (MSCs) in patients with hypertrophic cardiomyopathy (HCM) compared to healthy individuals. The pathogenesis of myocardial hypertrophy in HCM is not fully understood. MSCs are involved in the process of neovascularization, fibrosis, and ventricular wall remodeling. Methods and results: We included 40 patients with HCM and 23 healthy individuals. Using flow cytometry, we measured MSCs in peripheral blood, as a population of CD45-/CD34-/CD90+ cells and also as a population of CD45-/CD34-/CD105+ cells. The resulting MSC counts were expressed as percentages of the total cells. Patients with HCM were found to have a greater percentage of circulating CD45-/CD34-CD34-/CD90+ cells compared to controls (0.0041 +/- 0.005% vs. 0.0007 +/- 0.001%, respectively, Pb<.001). No significant difference in circulating CD45-/CD34-/CD105+ cells in the peripheral blood was found between HCM patients and controls (0.016 +/- 0.018% vs. 0.012 +/- 0.014%, respectively, P=.4). Notably, circulating CD45-/CD34-/CD90+ cells were positively correlated with left ventricular mass index (r=0.54, Pb<.001). Conclusions: Patients with HCM reveal an increased mobilization of MSCs compared to healthy individuals. Although further research is needed to reveal the clinical significance of our findings, our data open a new dimension in the pathophysiology of the disease and may indicate new future therapeutic possibilities. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码：149 / 153
页数：5
相关论文
共 50 条
  • [21] Modeling hypertrophic cardiomyopathy with human induced pluripotent stem cells
    Ojala, M.
    Rajala, K.
    Polonen, R-P.
    Larsson, K.
    Aalto-Setala, K.
    CARDIOVASCULAR RESEARCH, 2014, 103
  • [22] Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
    Fang, Lu
    Ellims, Andris H.
    Moore, Xiao-lei
    White, David A.
    Taylor, Andrew J.
    Chin-Dusting, Jaye
    Dart, Anthony M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [23] Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
    Lu Fang
    Andris H. Ellims
    Xiao-lei Moore
    David A. White
    Andrew J. Taylor
    Jaye Chin-Dusting
    Anthony M. Dart
    Journal of Translational Medicine, 13
  • [24] Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
    Fang, L.
    Ellims, A.
    Moore, X. -L.
    White, D.
    Taylor, A.
    Chin-Dusting, J.
    Dart, A.
    EUROPEAN HEART JOURNAL, 2015, 36 : 452 - 452
  • [25] Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathy
    Gudkova, A. Ya
    Davidova, V. G.
    Bezhanishvili, T. G.
    Pyko, S. A.
    Zarayskiy, M., I
    TERAPEVTICHESKII ARKHIV, 2020, 92 (04): : 51 - 56
  • [26] Quest for Circulating Mesenchymal Stem Cells in Man.
    Hoogduijn, M.
    Engela, A.
    Verstegen, M.
    Korevaar, S.
    Roemeling-van Rhijn, M.
    Franquesa, M.
    de Jonge, J.
    IJzermans, J.
    Weimar, W.
    Betjes, M.
    van der Laan, L.
    Baan, C.
    TRANSPLANTATION, 2014, 98 : 338 - 338
  • [27] Quest for Circulating Mesenchymal Stem Cells in Man.
    Hoogduijn, M.
    Engela, A.
    Verstegen, M.
    Korevaar, S.
    Roemeling-van Rhijn, M.
    Franquesa, M.
    de Jonge, J.
    IJzermans, J.
    Weimar, W.
    Betjes, M.
    van der Laan, L.
    Baan, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 338 - 338
  • [28] Randomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy
    Hare, Joshua M.
    Heldman, Alan W.
    McNiece, Ian
    Velazquez, Darcy L. DiFede
    Zambrano, Juan P.
    Suncion, Viky
    Tracy, Melissa
    Gerstenblith, Gary
    Fishman, Joel E.
    Ghersin, Eduard
    Johnston, Peter
    Brinker, Jeffrey
    Breton, Elayne
    Davis, Janice
    Byrnes, John
    Mendizabal, Adam M.
    Lowery, Maureen H.
    Da Sliva, Jose
    Schulman, Ivonne
    Ruiz, Phillip
    Amador, Alexandra
    Altman, Peter
    Rouy, Didier
    Foo, Cheryl Wong Po
    CIRCULATION, 2012, 126 (23) : 2784 - 2784
  • [29] Intra-coronary injection of mesenchymal stem cells in patients with severe ischemic cardiomyopathy
    Goncalvesova, E
    Lakota, J
    Fridrich, V
    Fabián, J
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 153A - 153A
  • [30] Elevated levels of circulating mesenchymal stem cells in patients with chronic hepatitis B and C
    Abrams, Julian A.
    Jacob, Vinita
    Manavalan, John S.
    Wang, Timothy C.
    Wang, Sheng-Wen
    GASTROENTEROLOGY, 2007, 132 (04) : A86 - A86
12345